Genmab, GSK, and Merck KGaA have all appointed new chief executives sourced internally, reflecting a trend toward continuity and leveraging internal expertise within leading biopharma firms. This leadership reshuffle follows recent strategic shifts including major acquisitions and evolving pipeline priorities, underscoring the importance of experienced stewardship amid a dynamic industry landscape.